1. previously diagnosed with covid-19 2. positive pregnancy test at the time of study entry in potentially fertile women 3. pregnant or breastfeeding women 4. subject who has received one or more doses of any vaccine for sars-cov-2 or who is scheduled to be vaccinated within the next 60 days 5. unable to provide informed consent 6. clear contraindication to epa 7. known hypersensitivity to the study drug 8. administration of a drug with anticoagulant effects (antiplatelet agents are allowed) 9. hemorrhagic diathesis (b) treatment arm: inclusion criteria: 1. 40 years of age or older and 2. covid 19 diagnosis confirmed with sars cov-2 test (rt-pcr) and 3. no more than 7 days from the onset of symptoms and 4. without clear indication for hospitalization (1-2 in the who covid-19 descriptive score).

1. previously diagnosed with covid-19 2. positive pregnancy test at the time of study entry in potentially fertile women 3. pregnant or breastfeeding women 4. subject who has received one or more doses of any vaccine for sars-cov-2 or who is scheduled to be vaccinated within the next 60 days 5. unable to provide informed consent 6. clear contraindication to epa 7. known hypersensitivity to the study drug 8. administration of a drug with anticoagulant effects (antiplatelet agents are allowed) 9. hemorrhagic diathesis (b) treatment arm: inclusion criteria: 1. 40 years of age or older and 2. covid 19 diagnosis confirmed with sars cov-2 test (rt-pcr) and 3. no more than 7 days from the onset of symptoms and 4. without clear indication for hospitalization (1-2 in the who covid-19 descriptive score).

previously diagnosed with covid-19 positive pregnancy test at the time of study entry in potentially fertile women pregnant or breastfeeding women subject who has received one or more doses of any vaccine for sars-cov-2 or who is scheduled to be vaccinated within the next 60 days unable to provide informed consent clear contraindication to epa known hypersensitivity to the study drug administration of a drug with anticoagulant effects (antiplatelet agents are allowed) hemorrhagic diathesis (b) treatment arm: inclusion criteria: 40 years of age or older and covid 19 diagnosis confirmed with sars cov-2 test (rt-pcr) and no more than 7 days from the onset of symptoms and without clear indication for hospitalization (1-2 in the who covid-19 descriptive score).

previously diagnosed with covid-19 positive pregnancy test at the time of study entry in potentially fertile women pregnant or breastfeeding women subject who has received one or more doses of any vaccine for sars-cov-2 or who is scheduled to be vaccinated within the next 60 days unable to provide informed consent clear contraindication to epa known hypersensitivity to the study drug administration of a drug with anticoagulant effects (antiplatelet agents are allowed) hemorrhagic diathesis (b) treatment arm: inclusion criteria: 40 years of age or older and covid 19 diagnosis confirmed with sars cov-2 test (rt-pcr) and no more than 7 days from the onset of symptoms and without clear indication for hospitalization (1-2 in the who covid-19 descriptive score).

1. previously diagnosed with covid-19 2. positive pregnancy test at the time of study entry in potentially fertile women 3. pregnant or breastfeeding women 4. subject who has received one or more doses of any vaccine for sars-cov-2 or who is scheduled to be vaccinated within the next 60 days 5. unable to provide informed consent 6. clear contraindication to epa 7. known hypersensitivity to the study drug 8. administration of a drug with anticoagulant effects (antiplatelet agents are allowed) 9. hemorrhagic diathesis (b) treatment arm: inclusion criteria: 1. 40 years of age or older and 2. covid 19 diagnosis confirmed with sars cov-2 test (rt-pcr) and 3. no more than 7 days from the onset of symptoms and 4. without clear indication for hospitalization (1-2 in the who covid-19 descriptive score).

1. previously diagnosed with covid-19 2. positive pregnancy test at the time of study entry in potentially fertile women 3. pregnant or breastfeeding women 4. subject who has received one or more doses of any vaccine for sars-cov-2 or who is scheduled to be vaccinated within the next 60 days 5. unable to provide informed consent 6. clear contraindication to epa 7. known hypersensitivity to the study drug 8. administration of a drug with anticoagulant effects (antiplatelet agents are allowed) 9. hemorrhagic diathesis (b) treatment arm: inclusion criteria: 1. 40 years of age or older and 2. covid 19 diagnosis confirmed with sars cov-2 test (rt-pcr) and 3. no more than 7 days from the onset of symptoms and 4. without clear indication for hospitalization (1-2 in the who covid-19 descriptive score).

1. currently presents with symptoms consistent with covid-19 or influenza-like symptoms 2. previously diagnosed with covid-19 3. pregnant or breastfeeding women 4. unable to provide informed consent 5. currently taking eicosapentaenoic acid (epa) or dietary fish oil supplements 6. known hypersensitivity to the study drug 7. administration of a durg with anticoagulant effects (antiplatelet agents are allowed) 8. hemorrhagic diathesis 9. history of recurrent paroxysmal atrial fibrillation (af) or persistent af

1. currently presents with symptoms consistent with covid-19 or influenza-like symptoms 2. previously diagnosed with covid-19 3. pregnant or breastfeeding women 4. unable to provide informed consent 5. currently taking eicosapentaenoic acid (epa) or dietary fish oil supplements 6. known hypersensitivity to the study drug 7. administration of a durg with anticoagulant effects (antiplatelet agents are allowed) 8. hemorrhagic diathesis 9. history of recurrent paroxysmal atrial fibrillation (af) or persistent af